Company: PTPI
Filing Date: 2025-03-18
Form Type: DEF 14A
Source: 0001104659-25-025104
Chunk: 30

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-18
Form: DEF 14A
Chunk 30
---
 convey or otherwise dispose of all or substantially all of our assets or we or another person
acquire more than 50% of our outstanding shares of Common Stock, then following such event, the holders of the Series B Warrants
will be entitled to receive upon exercise of the Series B Warrants the same kind and amount of securities, cash or property which
the holders would have received had they exercised the Series B Warrants immediately prior to such fundamental transaction. Any successor
to us or surviving entity shall assume the obligations under the Series B Warrants. Additionally, as more fully described in the
Series B Warrants, in the event of certain fundamental transactions, the holders of the Series B Warrants will be entitled to
receive consideration in an amount equal to the Black Scholes value of Series B Warrants on the date of consummation of such transaction.

Transferability

Subject to applicable laws, a Series B Warrant may be transferred
at the option of the holder upon surrender of the Series B Warrant to us together with the appropriate instruments of transfer.

Fractional Shares

No fractional shares of Common Stock will be issued upon the exercise
of the Series B Warrants. Rather, the number of shares of Common Stock to be issued will, at our election, either be rounded up to
the next whole share or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the exercise price.

Trading Market

There is no established trading market for the Series B Warrants,
and we do not expect an active trading market to develop. We do not intend to apply to list the Series B Warrants on any securities
exchange or other trading market. Without a trading market, the liquidity of the Series B Warrants will be extremely limited.

Right as a Stockholder

Except as otherwise provided in the Series B Warrants or by virtue
of such holder’s ownership of our shares of Common Stock, the holder of a Series B Warrant does not have the rights or privileges
of a holder of our Common Stock, including any voting rights, until the holder exercises the Series B Warrant.

<div align='center'>19</div>

Waivers and Amendments

The Series B Warrants may be modified or amended, or the provisions
thereof waived with the written consent of the Company and the respective holder.

Approval of the Issuance Proposal

Our Common Stock is listed
on The Nasdaq Capital Market, and as a result, we are subject to Nasdaq’s